To confirm that the enhanced migration of MSCs was due to an increased CXCL12 concentration in the FSHD myoblast‐conditioned media, we used neutralizing antibodies against CXCL12 and AMD3100, a synthetic antagonist of the CXCL12 receptor CXCR4. This evidence concerns the gene CXCR4 and facioscapulohumeral muscular dystrophy.